Authors:
Rubin, DL
Desser, TS
Semelka, R
Brown, J
Nghiem, HV
Stevens, WR
Bluemke, D
Nelson, R
Fultz, P
Reimer, P
Ho, V
Kristy, RM
Pierro, JA
Citation: Dl. Rubin et al., A multicenter, randomized, double-blind study to evaluate the safety, tolerability, and efficacy of OptiMARK (gadoversetamide injection) compared with magnevist (gadopentetate dimeglumine) in patients with liver pathology: Results of a phase III clinical trial, J MAGN R I, 9(2), 1999, pp. 240-250
Authors:
Swan, SK
Baker, JF
Free, R
Tucker, RM
Barron, B
Barr, R
Seltzer, S
Gazelle, GS
Maravilla, KR
Barr, W
Stevens, GR
Lambrecht, LJ
Pierro, JA
Citation: Sk. Swan et al., Pharmacokinetics, safety, and tolerability of gadoversetamide injection (OptiMARK) in subjects with central nervous system or liver pathology and varying degrees of renal function, J MAGN R I, 9(2), 1999, pp. 317-321